Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma

The low resection and high recurrence rates in hepatocellular carcinoma (HCC) are the major challenges to improving prognosis. Neoadjuvant and conversion therapies are underlying strategies to overcome these challenges. To date, no guideline or consensus has been published on the neoadjuvant and con...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Hai-Tao, Cai, Jian-Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Expert Consensus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704274/
https://www.ncbi.nlm.nih.gov/pubmed/35068855
http://dx.doi.org/10.3748/wjg.v27.i47.8069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704274/
https://www.ncbi.nlm.nih.gov/pubmed/35068855
http://dx.doi.org/10.3748/wjg.v27.i47.8069

Ejemplares similares